This is the Nexus Narcolepsy registry, a joint venture of Jazz Pharmaceuticals, Narcolepsy Network, and Wake Up Narcolepsy. See ClinicalTrials.gov. NOW RECRUITING people with narcolepsy internationally: CLICK HERE to register.
NOW RECRUITING in the U.S.: CLICK HERE. Axsome Therapeutics is enrolling people with narcolepsy with cataplexy (only) for a study of the efficacy of AXS-12 (reboxetine) for treatment of cataplexy and excessive daytime sleepiness. AXS-12 is an oral norepinephrine reuptake inhibitor (NRI).
NOW RECRUITING in the USA: CLICK HERE. Jazz Pharmaceuticals also has a study arm for OSA (obstructive sleep apnea), which is also RECRUITING – CLICK HERE. And a separate 4-week study of safety, efficacy, and pharmacokinetics of JZP-110 in Parkinson’s disease with excessive daytime sleepiness, which is also currently RECRUITING – CLICK HERE. There are also several separate studies of JZP-110, which are ongoing but no longer recruiting: 1) 12-week safety and efficacy in OSA – CLICK HERE; 2) 12-week safety and efficacy in narcolepsy – CLICK HERE; 3) long-term safety in narcolepsy and OSA – CLICK HERE; and 4) 6-week study of safety and efficacy in OSA – CLICK HERE. See Past Research Studies tab for current results.
Jazz Pharmaceuticals’ trial completed: CLICK HERE. ADX-N05 is another name for JZP-110, as above.
NOW RECRUITING in S. Korea: CLICK HERE. Medicine available for off-label treatment in the USA.
Theranexus THN102 (modafinil/flecanide combo). NOW RECRUITING in France: CLICK HERE. For more info: 1) First Clinical Study Completed on Effectiveness of Possible Narcolepsy Drug THN102. Flecainide is “an antiarrhythmic agent used in this instance at very low dosages and for its modulating effects on the glial connexins”; and 2) Hungary OKs Phase 2 Clinical Trial of Drug Candidate for Excessive Daytime Sleepiness in Parkinson’s.
NOW RECRUITING in France: CLICK HERE.
NOW RECRUITING at Tangdu Hospital in Xi’an, Shaanxi Province, China: CLICK HERE.